tirzepatide off patent Off-patent semaglutide in 2026: the next revolution in anti-obesity medications In weight loss battle, Novo

Special report: potential strategies for addressing GLP-1 and dual GLP-1/GIP receptor agonist shortages

Obesity has a negative effect on reproductive potential primarily due to functional alterations of the hypothalamic-pituitary-ovarian (HPO) axis

Stopping tirzepatide may not be necessary to reverse hair loss, as shedding is often due to weight fluctuations rather than the drug itself

[DOI] [PMC free article] [PubMed] [Google Scholar] 146.Gutgesell RM, Nogueiras R, Tschp MH, et al

All prescriptions obtained via Hers are provided by licensed Canadian healthcare providersthe same as you would get at a hospital, doctors office, or clinic